Trastuzumab Emtansine Patent Status Overview
Trastuzumab emtansine (Kadcyla), developed by Genentech (Roche), has multiple patents protecting its composition, methods of use, and manufacturing. Some have expired, opening opportunities for licensing expired intellectual property or related know-how, though licensing typically applies to active patents. Expired patents enter the public domain and cannot be exclusively licensed, but non-expired ones can be. Check DrugPatentWatch.com for the latest expiration data and licensing potential [1].
Which Trastuzumab Emtansine Patents Have Expired?
Several U.S. patents listed for Kadcyla in the FDA's Orange Book have expired:
- US 7,097,841 (conjugates of synthetic and natural toxins): Expired July 22, 2022.
- US 7,622,563 (methods for preparing maytansinoid conjugates): Expired December 15, 2023.
- US 8,119,134 (related antibody-drug conjugates): Expired October 2023.
These cover core elements like the emtansine payload and conjugation technology. Globally, equivalents like EP 1 289 528 expired around 2021-2022 in Europe [1][2].
Can Expired Patents Be Licensed?
No, expired patents cannot be licensed exclusively—they are free to use by anyone without royalties. However:
- Residual know-how, trade secrets, or data packages from development can sometimes be licensed separately.
- Companies like ImmunoGen (original emtansine licensor to Genentech) have licensed related platforms post-expiry for generics or biosimilars.
For non-expired patents (e.g., US 8,337,856 on specific formulations, expires 2028), licensing is possible via Roche/Genentech deals [1].
Active Patents Blocking Market Entry
Key unexpired patents include:
| Patent Number | Focus | Expiration |
|---------------|--------|------------|
| US 8,816,055 | HER2 antibody-maytansinoid conjugates | 2030 |
| US 7,994,298 | Treatment methods for cancer | 2029 (pediatric exclusivity to 2030) |
| US 10,093,739 | Stable formulations | 2033 |
These delay full generic/biosimilar competition until ~2033, with some method patents expiring sooner [1][3].
Licensing Opportunities for Developers
- Biosimilar Makers: License remaining Genentech patents or cross-license with ImmunoGen's maytansinoid tech to navigate litigation risks. Companies like Biocon and Reliance Life Sciences have pursued this.
- Who to Contact: Roche/Genentech for active IP; check ImmunoGen (now AbbVie subsidiary) for payload licensing.
- Recent Deals: No public expired patent licenses reported, but 2023 saw biosimilar filings challenging patents, potentially leading to settlements with licensing terms [2].
Biosimilar Timeline and Challenges
First Kadcyla biosimilars could launch post-2028 for some indications, but formulation patents extend to 2033. Pending litigations (e.g., vs. Samsung Bioepis) may accelerate via settlements. Track FDA approvals for updates [3].
Sources:
[1]: DrugPatentWatch.com - Kadcyla Patents
[2]: FDA Orange Book - Trastuzumab Emtansine
[3]: USPTO Patent Database